Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA

Fig. 2

Kaplan–Meier estimates of PFS by treatment group and OS by treatment group. a Investigator-assessed PFS (primary endpoint) by treatment (ITT population), in which no significant difference was found for G-CHOP compared with R-CHOP. b OS by treatment (ITT population), which showed no significant difference in survival between treatment groups. *Stratified by planned number of CHOP cycles and IPI score. CI, confidence interval; G-CHOP, obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; ITT, intent-to-treat; HR, hazard ratio; PFS, progression-free survival; OS, overall survival; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us